Cytokinetics (CYTK) Coverage Shifted at Piper Sandler, PT Raised to $50
Tweet Send to a Friend
Piper Sandler analyst Yasmeen Rahimi assumed coverage of Cytokinetics (NASDAQ: CYTK) and raised the price target on to $50.00 (from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
